百克生物将交上市后首份年亏损成绩单

Core Viewpoint - The company, Baike Bio, is expected to report its first annual net loss since its IPO in 2021, with a projected net profit loss of between -280 million to -220 million yuan for 2025, representing a year-on-year decline of 194.79% to 220.64% [1][3] Financial Performance - The projected net profit loss for 2025 is between -300 million to -240 million yuan after deducting non-recurring items, indicating a year-on-year decline of 204.43% to 230.54% [3] - The company has faced a decline in sales revenue from its main product, the herpes zoster live attenuated vaccine, due to factors such as public awareness of the disease and vaccination willingness [3][4] Market Challenges - The company attributes its performance challenges to intensified industry competition, decreased public willingness to vaccinate, and a declining birth rate [3][4] - The sales revenue of the herpes zoster vaccine has decreased, with confirmed revenue facing returns due to expiration before vaccination [3] Pricing Strategy - In response to market conditions, the company has actively adjusted the price of the herpes zoster vaccine, reducing it from 1375 yuan to 464 yuan, a decrease of over 66% [3][4] - The company has previously implemented discount pricing strategies to enhance public awareness and promote vaccination among the elderly [4] Inventory Management - The company has made provisions for inventory impairment based on the principle of prudence, reflecting a realistic financial status by accounting for products expected to have unsold inventory [4] Future Strategies - The company is focusing on multiple marketing initiatives to activate market potential, including optimizing pricing strategies and expanding product promotion channels [5][6] - R&D innovation is positioned as a strategic priority, with ongoing projects in various vaccine types, including pediatric and therapeutic vaccines, aiming to establish a solid foundation for future growth [6]